Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
40/ taken first · 1 trial · 1 indication
Drug Liking/Disliking Assessment on a 101 point bipolar visual analog scale (VAS) used to assess response to the question "Do you dislike or like the drug effect you are feeling now?" and anchored in the center with "Neither like nor dislike" (score of 50), on the left with "Dislike an awful lot" (score of 0) and on the right with "Like an awful lot" (score of 100).
| Arm | Type | Description |
|---|---|---|
| 40/0mg taken first | ACTIVE_COMPARATOR | 8x oxycodone/niacin 5/0mg tablets |
| 80/0mg taken first | ACTIVE_COMPARATOR | 8x oxycodone/niacin 10/0mg tablets |
| 40/240mg taken first | EXPERIMENTAL | 8x oxycodone/niacin 5/30mg tablets |
| 80/480mg taken first | EXPERIMENTAL | 8x oxycodone/niacin 10/60mg tablets |
| 0/0mg taken first | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| 40/0mg taken first | DRUG | 8x Oxycodone/Niacin 5/0mg tablets All arms taken with a 48 hour washout between doses |
| 80/0mg taken first | DRUG | 8x Oxycodone/Niacin 10/0mg tablets All arms taken with a 48 hour washout between doses |
| 40/240mg taken first | DRUG | 8x Oxycodone/Niacin 5/30mg tablets All arms taken with a 48 hour washout between doses |
| 80/480mg taken first | DRUG | 8x Oxycodone/Niacin 10/60mg tablets All arms taken with a 48 hour washout between doses |
| 0/0mg taken first | DRUG | Placebo All arms taken with a 48 hour washout between doses |
Inclusion Criteria: * Subject is male or female between 18 and 55 years old. * Subject is in generally good health, including no history of pulmonary disease, and has a body mass index (BMI) within 18-33 kg/m2. * Subject is a recreational opioid user (i.e., at least 10 occasions within the past 12 ...
Acurox is an investigational small molecule being studied for opioid abuse. It was evaluated in a Phase 2 clinical trial in non-dependent recreational opioid users to assess its relative abuse potential. The drug is not approved and remains in clinical development.
Acurox is being developed by Pfizer, Inc. (NYSE: PFE). The company conducted a Phase 2 study of the drug in the United States for opioid abuse.
Acurox is in Phase 2 clinical development. A Phase 2 study of the drug has been completed. Acurox is investigational and has not been approved by the FDA.
Acurox was studied in a completed Phase 2 trial, NCT01030406, titled "Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users." The trial enrolled 49 participants in the United States and was randomized, double-blind, and placebo-controlled.
Acurox is the name used in clinical trials for this investigational drug. No alternative names have been reported for Acurox in the context of its development for opioid abuse.